Capecitabine
Showing 26 - 50 of 2,332
Colorectal Cancer, Colorectal Cancer Stage IV Trial (Fruquintinib Plus Capecitabine, Capecitabine)
Not yet recruiting
- Colorectal Cancer
- Colorectal Cancer Stage IV
- Fruquintinib Plus Capecitabine
- Capecitabine
- (no location specified)
Jul 9, 2022
Nasopharyngeal Carcinoma, Maintenance Therapy Trial in Guangzhou (Capecitabine/Placebo combined with treprizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Maintenance Therapy
- Capecitabine/Placebo combined with treprizumab
-
Guangzhou, Guangdong, ChinaSunYat-senU
May 11, 2023
Breast, Metastatic, Triple Negative Trial in Gainesville, Jacksonville (Capecitabine, Sarilumab 150mg or 200 mg plus
Active, not recruiting
- Breast
- +4 more
- Capecitabine
- +2 more
-
Gainesville, Florida
- +1 more
Feb 2, 2023
Hormone Receptor-positive Breast Cancer Trial in Tampa (Cemiplimab, Capecitabine)
Recruiting
- Hormone Receptor-positive Breast Cancer
- Cemiplimab
- Capecitabine
-
Tampa, FloridaMoffitt Cancer Center
Dec 30, 2022
Colorectal Cancer Trial in Hangzhou (Fruquintinib Plus Capecitabine, Bevacizumab Plus Capecitabine)
Recruiting
- Colorectal Cancer
- Fruquintinib Plus Capecitabine
- Bevacizumab Plus Capecitabine
-
Hangzhou, Zhejiang, Chinathe Second Affiliated Hospital of Medical College of Zhejiang Un
Jul 25, 2022
Pancreatic Cancer Trial in United States (Gemcitabine and Capecitabine)
Recruiting
- Pancreatic Cancer
- Gemcitabine and Capecitabine
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Dec 31, 2022
Capecitabine With Adjuvant Radiotherapy in Treatment of Early
Not yet recruiting
- Breast Cancer
- Radiotherapy
- (no location specified)
Jan 30, 2023
Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer Trial (TST001, CapOx or mFOLFOX6 and NIVO or (Substudy)
Not yet recruiting
- Gastric Cancer
- +2 more
- TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
- Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
- (no location specified)
Oct 16, 2023
Colorectal Cancer Metastatic, Peritoneal Carcinomatosis Trial in Amsterdam (Galunisertib plus capecitabine)
Not yet recruiting
- Colorectal Cancer Metastatic
- Peritoneal Carcinomatosis
- Galunisertib plus capecitabine
-
Amsterdam, Netherlands
- +1 more
Jan 17, 2023
Metastatic Colorectal Cancer Trial (Anti-PD-1 Monoclonal Antibody + Capecitabine)
Not yet recruiting
- Metastatic Colorectal Cancer
- Tislelizumab + Capecitabine
- Best supportive care
- (no location specified)
Sep 22, 2022
HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))
Not yet recruiting
- HER2-positive Breast Cancer
- Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
- (no location specified)
Jul 20, 2023
Metastatic HER2 Negative Breast Carcinoma, Brain Metastases, Capecitabine Trial in Changsha (UTD1 combined with capecitabine)
Recruiting
- Metastatic HER2 Negative Breast Carcinoma
- +3 more
- UTD1 combined with capecitabine
-
Changsha, ChinaQuchang Ouyang
Sep 9, 2022
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer Trial in Australia, China
Recruiting
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- LBL-007
- +3 more
-
Benowa, Queensland, Australia
- +7 more
Jan 30, 2023
Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction Trial run by the NCI (Paclitaxel, Capecitabine, BardPort
Recruiting
- Gastric Adenocarcinoma
- +3 more
- Paclitaxel
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)
Active, not recruiting
- Breast Cancer
- Capecitabine
- Aromatase Inhibitor
-
Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen Uni
Jan 27, 2023
Breast Cancer Trial in Zhengzhou (Capecitabine+endocrine therapy, Placebo+endocrine therapy)
Recruiting
- Breast Cancer
- Capecitabine+endocrine therapy
- Placebo+endocrine therapy
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Nov 19, 2022
Triple Negative Breast Cancer Trial in Guangzhou (Capecitabine, Tucidinostat)
Recruiting
- Triple Negative Breast Cancer
- Capecitabine
- Tucidinostat
-
Guangzhou, Guangdong, ChinaSun-yat sen university cancer center
Nov 1, 2022
Brain Metastases, HER2-positive Breast Cancer Trial (Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine)
Not yet recruiting
- Brain Metastases
- HER2-positive Breast Cancer
- Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
- (no location specified)
Jan 10, 2023
Advanced Breast Cancer Trial (Dalpiciclib+ letrozole +capecitabine)
Not yet recruiting
- Advanced Breast Cancer
- Dalpiciclib+ letrozole +capecitabine
- (no location specified)
Jul 21, 2022
Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct Trial run by the National Cancer Institute (NCI) (oxaliplatin,
Not yet recruiting
- Biliary Cancer
- +2 more
- oxaliplatin
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
May 13, 2023
Breast Cancer Metastatic, Leptomeningeal Metastasis Trial (Tucatinib Oral Tablet, Capecitabine tablets, Trastuzumab Injection)
Not yet recruiting
- Breast Cancer Metastatic
- Leptomeningeal Metastasis
- Tucatinib Oral Tablet
- +2 more
- (no location specified)
Mar 23, 2023
Recurrent Pituitary Adenomas Trial in New York (Capecitabine, Temozolomide)
Terminated
- Recurrent Pituitary Adenomas
- Capecitabine
- Temozolomide
-
New York, New YorkWeill Cornell Medical College
Jul 15, 2022
Metastatic Pancreatic Cancer Trial in Singapore (Low Dose OXIRI (LD-OXIRI))
Not yet recruiting
- Metastatic Pancreatic Cancer
- Low Dose OXIRI (LD-OXIRI)
-
Singapore, SingaporeNational Cancer Centre, Singapore
Jun 29, 2023